双榜加冕！麦科奥特闪耀“肽未来”2025中国多肽药物产业创新双榜单
MICOT
点击蓝字 关注我们
Slide to view different languages
<< 滑动查看不同语言 >>
双榜加冕！麦科奥特闪耀“肽未来”
2025中国多肽药物产业创新双榜单
近日，在备受瞩目的第五届多肽产业创新发展论坛上，“肽未来”—2025中国多肽药物产业创新发展榜单正式揭晓。陕西麦科奥特医药科技股份有限公司（以下简称“麦科奥特”）凭借卓越的创新实力与行业影响力，一举荣登“中国多肽药物创新潜力榜”及“中国多肽领域人气TOP榜”两项重量级榜单，彰显硬核创新实力与行业标杆地位。
本次评选由药渡集团与E药学苑联合发起，覆盖中国多肽药物产业十五年核心创新成果，从全产业链视角遴选出各维度标杆企业。麦科奥特此次双榜加冕，不仅是对其核心技术实力与差异化竞争优势的高度认可，更是对其在多肽药物领域持续深耕、引领创新的权威肯定。
MICOT
论坛期间，公司CMC副总裁受邀出席，与行业顶尖专家围绕“多肽产业化破局之路”展开圆桌研讨。结合麦科奥特在多肽创新药研发与产业化方面的实战经验，分享了关于技术突破、管线布局及全球竞争的深刻洞察，为产业高质量发展贡献了宝贵智慧。同时在“前沿技术与临床论坛”分享了公司发展历程与临床研发管线，发出合作邀约。现场多家企业与麦科奥特达成合作意向，合作方向涵盖原料药生产、辅料供应、制剂生产、新技术研发、产品销售等。
作为专注于多肽药物研发的创新型生物医药企业，麦科奥特聚焦心血管、代谢性疾病等重大领域，致力于开发具有全球竞争力的“First-in-class”创新药。公司凭借独特的多肽药物设计平台与丰富的产品管线，多款在研产品展现出巨大的临床价值和商业化潜力，这与“创新潜力榜”的评选标准高度契合。
当前，中国多肽药物产业正迈入黄金发展期。麦科奥特将以此次获奖为契机，持续强化在多肽领域的专业优势，加速推进临床管线与国际化合作，力争成为全球双功能多肽药物研发领军企业，为中国多肽产业高质量发展注入力量。
原文链接：https://mp.weixin.qq.com/s/VF-0zl0cJ2d5VzuHSbi6lw
图片来源：药渡微信公众号
MICOT
欢迎关注
麦科奥特｜MICOT
Micot Bio Shines on "Peptide Future" 2025 China Peptide Drug Industry Innovation Double Rankings
Recently, at the highly anticipated 5th Peptide Industry Innovation and Development Forum, the "Peptide Future" — 2025 China Peptide Drug Industry Innovation Rankings were officially unveiled. Shaanxi Micot Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Micot Bio") secured two prestigious spots on both the "China Peptide Drug Innovation Potential Ranking" and the "China Peptide Sector Popularity TOP Ranking," showcasing its strong innovative capabilities and industry leadership.
The rankings were jointly initiated by PharmaDIG and E Pharmacy, covering fifteen years of core innovative achievements in China's peptide drug industry, and selecting benchmark enterprises across the entire industrial chain from multiple dimensions. Micot Bio’s double honor not only represents strong recognition of its core technological strength and differentiated competitive advantages but also serves as an authoritative endorsement of its continuous deep cultivation and innovation leadership in the peptide drug field.
MICOT
During the forum, the company’s CMC Vice President was invited to participate in a roundtable discussion with top industry experts on the theme "Breaking Through Bottlenecks in Peptide Industrialization." Drawing on Micot Bio’s hands-on experience in peptide drug R&D and industrialization, the VP shared deep insights into technological breakthroughs, pipeline strategies, and global competition, contributing valuable perspectives to the high-quality development of the industry. Additionally, during the "Frontier Technology and Clinical Forum," the VP presented the company’s development journey and clinical R&D pipeline, extending collaboration invitations. On-site, multiple enterprises expressed cooperation intentions with Micot Bio in areas including API production, excipient supply, formulation manufacturing, new technology R&D, and product sales.
As an innovative biopharmaceutical company focused on peptide drug R&D, Micot Bio is dedicated to addressing major therapeutic areas such as cardiovascular and metabolic diseases, striving to develop globally competitive "First-in-class" innovative drugs. Leveraging its unique peptide drug design platform and a rich product pipeline, several of the company’s pipeline candidates have demonstrated significant clinical value and commercial potential, aligning closely with the selection criteria of the "Innovation Potential Ranking."
At present, China’s peptide drug industry is entering a golden period of development. Seizing this recognition as an opportunity, Micot Bio will continue to strengthen its professional advantages in the peptide field, accelerate the advancement of its clinical pipeline and international collaborations, and strive to become a global leader in dual-function peptide drug R&D, injecting momentum into the high-quality development of China’s peptide industry.
原文链接：https://mp.weixin.qq.com/s/VF-0zl0cJ2d5VzuHSbi6lw
图片来源：药渡微信公众号
MICOT
欢迎关注
麦科奥特｜MICOT
详情
奋斗为本、求是创新、协作共赢
